MCID: BRD004
MIFTS: 47

Borderline Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

About this section

Aliases & Descriptions for Borderline Personality Disorder:

Name: Borderline Personality Disorder 11 50 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:10930
ICD1030 F60.3
ICD9CM32 301.83
SNOMED-CT62 192488005, 20010003
MeSH39 D001883
NCIt45 C92633

Summaries for Borderline Personality Disorder

About this section
Disease Ontology:11 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary: Borderline Personality Disorder is related to personality disorder and antisocial personality disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are Dopamine metabolism and noradrenaline and adrenaline degradation. Affiliated tissues include brain, amygdala and bone, and related mouse phenotypes are integument and muscle.

Wikipedia:71 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder, is a... more...

Related Diseases for Borderline Personality Disorder

About this section

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 112)
idRelated DiseaseScoreTop Affiliating Genes
1personality disorder31.0BDNF, COMT, HTR1A, HTR2A, HTR2C, MAOA
2antisocial personality disorder30.3HTR1A, HTR2A
3schizophrenia28.6BDNF, COMT, HTR1A, HTR1B, HTR2A, HTR2C
4multiple personality disorder27.5AVPR1A, BDNF, COMT, HTR1A, HTR1B, HTR2A
5sexual sadism10.8
6impulse control disorder10.8
7bipolar disorder10.2
8conjunctival pigmentation10.2MAOA, SLC6A4
9cholestasis-lymphedema syndrome10.2COMT, MAOA
10chondrodysplasia lethal recessive10.2COMT, TPH1
11polyneuropathy10.2HTR1A, HTR2A
12aryepiglottic fold cancer10.2HTR1A, HTR2A
13ornithosis10.2MAOA, SLC6A4
14splenic abscess10.2HTR2A, SLC6A4
15nephronophthisis 1310.2COMT, HTR2A, SLC6A4
16strongyloidiasis10.2COMT, MAOA, SLC6A4
17apperceptive agnosia10.2COMT, HTR1A, SLC6A4
18autism spectrum disorder10.1BDNF, COMT, SLC6A4
19bulimia nervosa10.1
20adult brainstem astrocytoma10.1HTR1A, MAOA, SLC6A4
21kidney pelvis papillary carcinoma10.1HTR1A, MAOA, SLC6A4
22neurogenic bladder10.1HTR2A, MAOA, SLC6A4
23teratoma with malignant transformation10.1BDNF, HTR2A
24tinea pedis10.1HTR1A, MAOA, SLC6A4
25pyromania10.1HTR2A, MAOA, SLC6A4
26euthyroid sick syndrome10.1HTR2A, SLC6A4
27attention deficit-hyperactivity disorder10.1
28substance dependence10.1
29hemochromatosis, type 2a10.1BDNF, COMT, MAOA
30carotid stenosis10.1COMT, MAOA, SLC6A4, TPH1
31bartter disease10.0HTR2A, SLC6A4, TPH2
32hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy10.0BDNF, COMT, HTR2A, SLC6A4
33basal cell carcinoma 310.0COMT, HTR2A, MAOA, TPH1
34mood disorder10.0
35somatoform disorder10.0
36eating disorder10.0
37hepatitis b reinfection following liver transplantation10.0HTR1A, HTR2A, MAOA, SLC6A4
38mucinous adenocarcinoma10.0BDNF, HTR1B, MAOA, SLC6A4
39lethal congenital contracture syndrome 110.0COMT, MAOA
40colorectal adenocarcinoma10.0COMT, MAOA, SLC6A4, TPH2
41hypereosinophilic syndrome10.0BDNF, HTR1B, MAOA, SLC6A4
42parotid gland cancer10.0COMT, HTR2A, TPH1
43cholesteatoma10.0BDNF, COMT, HTR2C, SLC6A4
44alexithymia10.0
45anxiety disorder10.0
46post-traumatic stress disorder10.0
47heroin dependence10.0
48epithelioid type angiomyolipoma10.0BDNF, HTR2A, SLC6A4
49chronic eosinophilic pneumonia9.9BDNF, COMT, HTR1A, MAOA, SLC6A4
50dry eye syndrome9.9HTR1A, HTR2A, HTR2C, SLC6A4

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Anxiety DisorderAcute Cystitis
Cerebral AtherosclerosisHypertension, Essential
Dependent Personality DisorderDysthymic Disorder
HypothyroidismSchizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to borderline personality disorder

Symptoms & Phenotypes for Borderline Personality Disorder

About this section

MGI Mouse Phenotypes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.8BDNF, HTR2C, NR3C1, SLC6A4, TPH1, TPH2
2MP:00053698.3AVPR1A, HTR1B, HTR2A, HTR2C, NR3C1, SLC6A4
3MP:00053798.3AVPR1A, BDNF, COMT, HTR1B, HTR2A, NR3C1
4MP:00053857.6AVPR1A, COMT, HTR1A, HTR1B, MAOA, NR3C1
5MP:00053767.1AVPR1A, BDNF, COMT, HTR1A, HTR2C, MAOA
6MP:00036316.6AVPR1A, BDNF, COMT, HTR1A, HTR2C, MAOA
7MP:00053866.4AVPR1A, BDNF, COMT, HTR1A, HTR1B, HTR2A

Drugs & Therapeutics for Borderline Personality Disorder

About this section

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 109)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Fluoxetineapproved, vet_approvedPhase 423854910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
3
Risperidoneapproved, investigationalPhase 4492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4
CitalopramapprovedPhase 4, Phase 251259729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
5
Lamotrigineapproved, investigationalPhase 418584057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
6Serotonin Uptake InhibitorsPhase 4, Phase 3, Phase 21587
7Serotonin AgentsPhase 4, Phase 3, Phase 23156
8
SerotoninPhase 4, Phase 3, Phase 2362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
9Psychotropic DrugsPhase 4, Phase 3, Phase 26430
10Tranquilizing AgentsPhase 4, Phase 3, Phase 24265
11Dopamine AgentsPhase 4, Phase 23836
12Central Nervous System DepressantsPhase 4, Phase 3, Phase 213403
13Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 223689
14Antipsychotic AgentsPhase 4, Phase 3, Phase 22401
15Serotonin AntagonistsPhase 4, Phase 21409
16Dopamine AntagonistsPhase 4, Phase 21093
17Autonomic AgentsPhase 4, Phase 3, Phase 210150
18Antiparkinson AgentsPhase 4, Phase 21574
19Cholinergic AgentsPhase 4, Phase 23992
20Cytochrome P-450 Enzyme InhibitorsPhase 43917
21Cholinergic AntagonistsPhase 4, Phase 21706
22Antidepressive Agents, Second-GenerationPhase 4, Phase 21311
23Antidepressive AgentsPhase 4, Phase 22736
24Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 23521
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
26Muscarinic AntagonistsPhase 4, Phase 21166
27ParasympatholyticsPhase 4, Phase 21085
28Cytochrome P-450 CYP2D6 InhibitorsPhase 4727
29Sodium Channel BlockersPhase 41593
30calcium channel blockersPhase 41985
31AnticonvulsantsPhase 4, Phase 32695
32Calcium, DietaryPhase 45713
33Diuretics, Potassium SparingPhase 41917
34Excitatory Amino AcidsPhase 41362
35Excitatory Amino Acid AntagonistsPhase 41347
36Omega 3 Fatty AcidNutraceuticalPhase 41018
37
Naltrexoneapproved, investigational, vet_approvedPhase 3, Phase 238816590-41-35360515
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
Celupan
D05113
DB00704
Depade
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
LS-92094
MLS002153483
MolPort-004-920-221
 
MorViva
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone (USAN/INN)
Naltrexone Hcl
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone [Usan:Ban:Inn]
Naltrexonum
Naltrexonum [INN-Latin]
PDSP2_000847
PTI-555
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
ReVia
SMP1_000206
SPBio_002071
UM-792
UNII-5S6W795CQM
Vivitrex
Vivitrol
Vivitrol (TN)
naltrexone
naltrexone (ReVia)
38
EthanolapprovedPhase 3, Phase 2213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
39
Olanzapineapproved, investigationalPhase 3399132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
40
Selegilineapproved, investigational, vet_approvedPhase 32714611-51-926757, 5195
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(−)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
C13H17N
CHEBI:9086
CHEMBL972
CID26757
Carbex
D03731
DB01037
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
 
Jumex
L-Deprenalin
L-Deprenyl
LS-30156
MolPort-000-883-771
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
SPBio_002544
STK640578
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline Transdermal System (STS) patch
Selegiline [INN:BAN]
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
Tocris-1095
UNII-2K1V7GP655
Yumex
ZINC19632633
Zelapar
l-E 250
selegiline
41Anti-Infective Agents, LocalPhase 3, Phase 21880
42Quetiapine FumaratePhase 3, Phase 2413111974-72-2
43Protective AgentsPhase 3, Phase 2, Phase 17443
44Anti-Infective AgentsPhase 3, Phase 2, Phase 122062
45NarcoticsPhase 3, Phase 23646
46AntiemeticsPhase 34022
47Narcotic AntagonistsPhase 3, Phase 2935
48Gastrointestinal AgentsPhase 38402
49
Oxytocinapproved, vet_approvedPhase 2, Phase 143950-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
50
Acetylcysteineapproved, investigationalPhase 2, Phase 1330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate

Interventional clinical trials:

(show top 50)    (show all 133)
idNameStatusNCT IDPhase
1Efficacy of Omega-3 Fatty Acids on Borderline Personality DisorderUnknown statusNCT00437099Phase 4
2Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality DisorderUnknown statusNCT00834834Phase 4
3Study of Lamotrigine Treatment of Affective Instability in Borderline Personality DisorderCompletedNCT00634062Phase 4
4Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality DisorderCompletedNCT00533117Phase 4
5Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality DisorderCompletedNCT00204347Phase 4
6Effects of Comorbid Personality Disorder on the Treatment of Bipolar I DisorderCompletedNCT00178061Phase 4
7BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality DisorderCompletedNCT00538135Phase 3
8Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)CompletedNCT00880919Phase 3
9Quetiapine Treatment for Symptoms Associated With Borderline Personality DisorderCompletedNCT00122070Phase 3
10Olanzapine in Patients With Borderline Personality DisorderCompletedNCT00091650Phase 3
11Efficacy and Safety of Olanzapine in Patients With Borderline Personality DisorderCompletedNCT00088036Phase 3
12Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality DisorderCompletedNCT01912391Phase 3
13Naltrexone in Borderline Personality DisorderTerminatedNCT00124839Phase 3
14Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol DependenceWithdrawnNCT00463775Phase 3
15Ziprasidone in the Treatment of Borderline Personality DisorderCompletedNCT00635921Phase 2
16Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder TreatmentCompletedNCT02125942Phase 1, Phase 2
17Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality DisorderCompletedNCT01103180Phase 2
18Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered PatientsCompletedNCT00254748Phase 2
19Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use DisorderCompletedNCT00145678Phase 2
20Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality DisorderCompletedNCT01133301Phase 2
21Treating PTSD in Patients With Borderline Personality DisorderCompletedNCT01081314Phase 1, Phase 2
22Treatment of Suicidal Women With Borderline Personality DisorderCompletedNCT00183651Phase 2
23Effectiveness of Group Based Schema Therapy in the Treatment of Personality DisordersCompletedNCT00247234Phase 2
24Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder SymptomsCompletedNCT01189812Phase 2
25Oxytocin as Adjunctive Therapy for SchizophreniaCompletedNCT01699997Phase 2
26Cognitive Therapy for PTSD in Addiction TreatmentCompletedNCT00685451Phase 1, Phase 2
27Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)RecruitingNCT02728778Phase 2
28A Novel Drug for Borderline Personality DisorderRecruitingNCT02097706Phase 2
29Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)RecruitingNCT01212588Phase 2
30Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood DisordersRecruitingNCT02824627Phase 2
31Acetaminophen and Social ProcessesActive, not recruitingNCT02108990Phase 2
32N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPDTerminatedNCT00539188Phase 2
33College Students Who Self-HarmWithdrawnNCT02522143Phase 2
34Creativity Group for Borderline Personality DisorderUnknown statusNCT01343550Phase 1
35Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress DisorderUnknown statusNCT00269139Phase 1
3620 Weeks DBT Group Skills Training StudyCompletedNCT01193205Phase 1
37Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in AdolescentsCompletedNCT01111734Phase 1
38Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsRecruitingNCT02149823Phase 1
39Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality DisorderUnknown statusNCT01602497
40Event Related Potentials in Borderline Personality Disorder and Major DepressionUnknown statusNCT01469663
41Guanfacine to Treat Borderline Personality DisorderUnknown statusNCT00358969
42Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive InterventionUnknown statusNCT01531634
43Cognitive Therapy Versus Supportive Therapy in Borderline Personality DisorderUnknown statusNCT00131781
44A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality DisorderUnknown statusNCT01033708
45DBT in Borderline Personality DisorderUnknown statusNCT00252031
46A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy AdultsUnknown statusNCT01426984
47DBT and Escitalopram in Borderline Personality DisorderUnknown statusNCT00255554
48Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality DisorderUnknown statusNCT01683136
49"The Effects of Oxytocin on Patients With Borderline Personality Disorder"Unknown statusNCT01243658
50Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT)Unknown statusNCT01904227

Search NIH Clinical Center for Borderline Personality Disorder


Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

About this section

Anatomical Context for Borderline Personality Disorder

About this section

MalaCards organs/tissues related to Borderline Personality Disorder:

36
Brain, Amygdala, Bone, Pituitary, Cortex, Testes, Ovary

Publications for Borderline Personality Disorder

About this section

Articles related to Borderline Personality Disorder:

(show top 50)    (show all 700)
idTitleAuthorsYear
1
The specificity of emotion dysregulation in adolescents with borderline personality disorder: comparison with psychiatric and healthy controls. (28078089)
2017
2
Altered Empathy for Psychological and Physical Pain in Borderline Personality Disorder. (28072040)
2017
3
Compelled to Risk: Does Sexual Compulsivity Explain the Connection Between Borderline Personality Disorder Features and Number of Sexual Partners? (28072043)
2017
4
Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. (28086181)
2017
5
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. (28072039)
2017
6
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. (28501733)
2017
7
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. (28072044)
2017
8
Resting cardiac function in adolescent non-suicidal self-injury: The impact of borderline personality disorder symptoms and psychosocial functioning. (28039803)
2017
9
Interpersonal Threat Sensitivity in Borderline Personality Disorder: An Eye-Tracking Study. (28072041)
2017
10
Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database. (28077135)
2017
11
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. (27144298)
2016
12
Cognitive and affective processing of social exclusion in borderline personality disorder and social anxiety disorder. (27616717)
2016
13
Creativity and borderline personality disorder: evidence from a voxel-based morphometry study. (27174566)
2016
14
A Neurobiological Model of Borderline Personality Disorder: Systematic and Integrative Review. (27603741)
2016
15
Evidence-Based Treatments for Borderline Personality Disorder: Implementation, Integration, and Stepped Care. (27603742)
2016
16
Long-Term Course of Borderline Personality Disorder. (27603806)
2016
17
Deficient amygdala-prefrontal intrinsic connectivity after effortful emotion regulation in borderline personality disorder. (28039553)
2016
18
Borderline Personality Disorder and the Effects of Instructed Emotional Avoidance or Acceptance in Daily Life. (27617652)
2016
19
Borderline Personality Disorder Symptoms in College Students: The Complex Interplay between Alexithymia, Emotional Dysregulation and Rumination. (27348858)
2016
20
Comparing the experience of voices in borderline personality disorder with the experience of voices in a psychotic disorder: A systematic review. (26912339)
2016
21
Biting the hand that feeds: current opinion on the interpersonal causes, correlates, and consequences of borderline personality disorder. (27990277)
2016
22
The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. (26182893)
2016
23
Sleep Problems in Childhood and Borderline Personality Disorder Symptoms in Early Adolescence. (27108717)
2016
24
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults. (27149691)
2016
25
Alcohol Craving and Consumption in Borderline Personality Disorder: When, Where, and with Whom. (28042520)
2016
26
Skills use and common treatment processes in dialectical behaviour therapy for borderline personality disorder. (27132175)
2016
27
An Investigation into the Roles of Theory of Mind, Emotion Regulation, and Attachment Styles in Predicting the Traits of Borderline Personality Disorder. (28050180)
2016
28
Preliminary Evidence for Emotion Dysregulation as a Mechanism Underlying Poor Sleep Quality in Borderline Personality Disorder. (27617649)
2016
29
Attentional Bias for Emotional Stimuli in Borderline Personality Disorder: A Meta-Analysis. (27642753)
2016
30
Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. (27990594)
2016
31
Object Relations Predicts Borderline Personality Disorder Symptoms Beyond Emotional Dysregulation, Negative Affect, and Impulsivity. (27176498)
2016
32
Borderline Personality Disorder in the Emergency Department: Good Psychiatric Management. (27603743)
2016
33
A new intervention for people with borderline personality disorder who are also parents: a pilot study of clinician acceptability. (27617096)
2016
34
Borderline personality disorder, but not euthymic bipolar I disorder, is associated with prolonged post-error slowing in sensorimotor performance. (27016660)
2016
35
The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. (27107850)
2016
36
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. (27093128)
2016
37
Impulsivity and aggression mediate regional brain responses in Borderline Personality Disorder: An fMRI study. (28039797)
2016
38
Outcome Uncertainty and Brain Activity Aberrance in the Insula and Anterior Cingulate Cortex Are Associated with Dysfunctional Impulsivity in Borderline Personality Disorder. (27199724)
2016
39
Prevalence of Borderline Personality Disorder in University Samples: Systematic Review, Meta-Analysis and Meta-Regression. (27171206)
2016
40
Borderline personality disorder and compulsive buying: A multivariate etiological model. (27124503)
2016
41
Interpersonal emotion regulation in Asperger's syndrome and borderline personality disorder. (27990657)
2016
42
Anxious adult attachment may mediate the relationship between childhood emotional abuse and borderline personality disorder. (27604841)
2016
43
The impact of stimulus arousal level on emotion regulation effectiveness in borderline personality disorder. (27203152)
2016
44
Abnormal white matter structural connectivity in treatment-naA^ve young adults with borderline personality disorder. (27611589)
2016
45
The association of posttraumatic stress disorder, complex posttraumatic stress disorder, and borderline personality disorder from a network analytical perspective. (27637074)
2016
46
Is There a Relationship Between Borderline Personality Disorder and Sexual Masochism in Women? (27600835)
2016
47
Suicidality and hospitalisation in patients with borderline personality disorder who experience auditory verbal hallucinations. (28049081)
2016
48
Aberrant DNA Methylation of rDNA and PRIMA1 in Borderline Personality Disorder. (26742039)
2016
49
Use of Clozapine for Borderline Personality Disorder: A Case Report. (27121437)
2016
50
The Main and Interactive Effects of Maternal Interpersonal Emotion Regulation and Negative Affect on Adolescent Girls' Borderline Personality Disorder Symptoms. (27185969)
2016

Variations for Borderline Personality Disorder

About this section

Expression for genes affiliated with Borderline Personality Disorder

About this section
Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for genes affiliated with Borderline Personality Disorder

About this section

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathwaysScoreTop Affiliating Genes
19.9COMT, MAOA
2
Show member pathways
9.9COMT, MAOA
39.8HTR2A, HTR2C
4
Show member pathways
9.6COMT, MAOA, SLC6A4
5
Show member pathways
9.6COMT, MAOA, TPH1
6
Show member pathways
9.4MAOA, SLC6A4, TPH2
8
Show member pathways
9.4MAOA, TPH1, TPH2
9
Show member pathways
9.3BDNF, HTR1A, HTR1B
10
Show member pathways
9.0HTR1A, HTR1B, HTR2A, HTR2C
119.0COMT, HTR1A, TPH1, TPH2
12
Show member pathways
8.9AVPR1A, HTR2A, HTR2C
137.7HTR1A, HTR1B, HTR2A, HTR2C, MAOA, SLC6A4
147.7HTR1A, HTR1B, HTR2A, HTR2C, MAOA, SLC6A4
157.5BDNF, HTR1A, HTR2A, MAOA, NR3C1, SLC6A4

GO Terms for genes affiliated with Borderline Personality Disorder

About this section

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of plasma membraneGO:00058877.3AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C, NRXN3

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 29)
idNameGO IDScoreTop Affiliating Genes
1catecholamine metabolic processGO:000658410.7COMT, MAOA
2dopamine catabolic processGO:004242010.7COMT, MAOA
3neurotransmitter catabolic processGO:004213510.6COMT, MAOA
4bone remodelingGO:004684910.6HTR1B, TPH1
5regulation of hormone secretionGO:004688310.6HTR1A, HTR2A
6negative regulation of synaptic transmission, glutamatergicGO:005196710.6HTR1B, HTR2A
7regulation of dopamine secretionGO:001405910.6HTR1B, HTR2A
8adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.5HTR1A, HTR1B
9phospholipase C-activating serotonin receptor signaling pathwayGO:000720810.5HTR2A, HTR2C
10positive regulation of phosphatidylinositol biosynthetic processGO:001051310.5HTR2A, HTR2C
11release of sequestered calcium ion into cytosolGO:005120910.5HTR2A, HTR2C
12behavioral fear responseGO:000166210.5HTR1A, HTR2C
13aromatic amino acid family metabolic processGO:000907210.4TPH1, TPH2
14indolalkylamine biosynthetic processGO:004621910.4TPH1, TPH2
15serotonin biosynthetic processGO:004242710.4TPH1, TPH2
16positive regulation of fat cell differentiationGO:004560010.2HTR2A, HTR2C, TPH1
17regulation of behaviorGO:005079510.2HTR1A, HTR1B, HTR2A
18circadian rhythmGO:000762310.2SLC6A4, TPH1, TPH2
19serotonin receptor signaling pathwayGO:000721010.2HTR1A, HTR2A, HTR2C
20activation of phospholipase C activityGO:000720210.1AVPR1A, HTR2A
21positive regulation of vasoconstrictionGO:004590710.1AVPR1A, HTR2A
22behaviorGO:00076109.8HTR1A, HTR1B, HTR2A, HTR2C
23sperm ejaculationGO:00427139.7AVPR1A, SLC6A4
24response to drugGO:00424939.6COMT, HTR1B, HTR2A, HTR2C, SLC6A4
25chemical synaptic transmissionGO:00072689.5HTR1B, HTR2A, HTR2C, NRXN3
26vasoconstrictionGO:00423109.5HTR1A, HTR1B, SLC6A4
27social behaviorGO:00351769.1AVPR1A, NRXN3, SLC6A4
28G-protein coupled receptor signaling pathwayGO:00071869.0AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C
29signal transductionGO:00071657.6AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C, NR3C1

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
11-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine bindingGO:007188610.5HTR2A, HTR2C
2amino acid bindingGO:001659710.4TPH1, TPH2
3oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygenGO:001671410.3TPH1, TPH2
4drug bindingGO:000814410.1HTR1B, HTR2A, HTR2C
5G-protein coupled serotonin receptor activityGO:00049939.7HTR1A, HTR1B, HTR2A, HTR2C
6neurotransmitter receptor activityGO:00305949.7HTR1A, HTR1B, HTR2A, HTR2C
7serotonin bindingGO:00513789.7HTR1A, HTR1B, HTR2A, HTR2C
8tryptophan 5-monooxygenase activityGO:00045109.7TPH1, TPH2
9G-protein coupled receptor activityGO:00049308.9AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C
10signal transducer activityGO:00048718.1AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C

Sources for Borderline Personality Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet